Evaluating the effect of a new interventional method for Herpes Pai
- Conditions
- Health Condition 1: null- Patients With established diagnosis of thoracic PH
- Registration Number
- CTRI/2018/03/012693
- Lead Sponsor
- niversity College of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
1. Patients should have a diagnosis of PHN with evident hyperalgesia and allodynia confined to
mid thoracic and lower thoracic dermatomes
2. Patients of PHN should have had pain for at least 4 weeks after healing of rash
3. Pain intensity >= 5 on 10cm visual analogue scale (VAS)
Exclusion criteria
1. Patients with history of neurological intervention for PHN
2. Evidence of other sources of pain that may confound the diagnosis
16
3. Known history of taking Pregabalin for the treatment of PHN in past 4 weeks
4. Patients with past history of myocardial infarction, diabetes mellitus, pancreatitis and vasculitis
5. Patients with recent history of surgery
6. Patients with evidence of severe renal impairment
7. Patients with history of alcohol consumption and smoking
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients achieving a VAS score of less than 3/10 at varying <br/ ><br>intervals following pulsed radiofrequency lesioningTimepoint: at the end of 1st week, at the end of 2nd <br/ ><br>week, at the end of 4th week, at the end of 8th week and end of 12th week.
- Secondary Outcome Measures
Name Time Method To assess pain intensity, quality of life and alteration in <br/ ><br>MicroRNA-133b expression.Timepoint: at baseline and at the end of 1st week, at the end of 2nd <br/ ><br>week, at the end of 4th week, at the end of 8th week and end of 12th week